The combination of a tumor-targeting mouse IL-12 fusion protein (NHS-muIL12) and the anti-PD-L1 antibody avelumab showed a stronger anti-tumor effect in the treatment of mouse breast cancer (EMT-6) and colon cancer (MC38) [76]. Here, CD274 is linked to neoplasm.